Literature DB >> 15502300

Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.

Jirí Brynda1, Pavlína Rezácová, Milan Fábry, Magdalena Horejsí, Renata Stouracová, Milan Soucek, Martin Hradílek, Jan Konvalinka, Juraj Sedlácek.   

Abstract

Depending on the excess of ligand used for complex formation, the HIV-1 protease complexed with a novel phenylnorstatine inhibitor forms crystals of either hexagonal (P6(1)) or orthorhombic (P2(1)2(1)2(1)) symmetry. The orthorhombic form shows an unusual complexity of crystal packing: in addition to one inhibitor molecule that is bound to the enzyme active site, the second inhibitor molecule is bound as an outer ligand at the protein interface. Binding of the outer ligand apparently increases the crystal-quality parameters so that the diffraction data allow solution of the structure of the complex at 1.03 A, the best resolution reported to date. The outer ligand interacts with all four surrounding HIV-1 protease molecules and has a bent conformation owing to its accommodation in the intermolecular space. The parameters of the solved structures of the orthorhombic and hexagonal forms are compared.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502300     DOI: 10.1107/S0907444904021572

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  8 in total

1.  Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.

Authors:  Milan Kozísek; Sandra Henke; Klára Grantz Sasková; Graeme Brendon Jacobs; Anita Schuch; Bernd Buchholz; Viktor Müller; Hans-Georg Kräusslich; Pavlína Rezácová; Jan Konvalinka; Jochen Bodem
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.

Authors:  Andrey Y Kovalevsky; Arun K Ghosh; Irene T Weber
Journal:  J Med Chem       Date:  2008-09-20       Impact factor: 7.446

3.  Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.

Authors:  Andrey Y Kovalevsky; Fengling Liu; Sofiya Leshchenko; Arun K Ghosh; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2006-08-04       Impact factor: 5.469

4.  Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.

Authors:  Mi Li; Gary S Laco; Mariusz Jaskolski; Jan Rozycki; Jerry Alexandratos; Alexander Wlodawer; Alla Gustchina
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

5.  From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease.

Authors:  Petr Cígler; Milan Kozísek; Pavlína Rezácová; Jírí Brynda; Zbyszek Otwinowski; Jana Pokorná; Jaromír Plesek; Bohumír Grüner; Lucie Dolecková-Maresová; Martin Mása; Juraj Sedlácek; Jochen Bodem; Hans-Georg Kräusslich; Vladimír Král; Jan Konvalinka
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-14       Impact factor: 11.205

6.  Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Martin Lepsík; Jirí Brynda; Pavlína Rezácová; Jana Václavíková; Ron M Kagan; Ladislav Machala; Jan Konvalinka
Journal:  Protein Sci       Date:  2008-06-17       Impact factor: 6.725

7.  Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Pavlína Rezácová; Jirí Brynda; Tatyana Yashina; Ron M Kagan; Jan Konvalinka
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

8.  Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region.

Authors:  Milan Kozísek; Klára Grantz Sasková; Pavlína Rezácová; Jirí Brynda; Noortje M van Maarseveen; Dorien De Jong; Charles A Boucher; Ron M Kagan; Monique Nijhuis; Jan Konvalinka
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.